News Industry News Boston Scientific Receives FDA Approval And CE Mark For AngioJet™ ZelanteDVT™ Thrombectomy Catheter November 30, 2015
News Industry News FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa October 20, 2015
News Industry News Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions August 24, 2015
News Industry News First U.S. Patients Enroll in Boehringer Ingelheim's Global RE-DUAL PCI™ and RE-CIRCUIT™ Trials Evaluating Pradaxa® (dabigatran etexilate mesylate) July 29, 2015
News Industry News NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in adults July 13, 2015
News Industry News Idarucizumab Reverses the Anticoagulant Effect of Dabigatran Within Minutes in Patient Study June 22, 2015
News Industry News New Study Evaluates “Triple Therapy” Regimens After Drug-Eluting Stenting in Patients Requiring Oral Anticoagulation September 15, 2014
News Industry News Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes September 02, 2014
News Industry News New study to investigate dabigatran etexilate for prevention of recurrent stroke in high-risk patients May 07, 2014
News Industry News World’s First Pulmonary Embolism Trial Comparing Endovascular Therapy to Standard of Care March 08, 2013
News Industry News FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation September 08, 2011
News Industry News EKOS Corporation Receives CE Mark to Treat Massive and Sub-Massive Pulmonary Embolism January 16, 2011
News Industry News Bayer’s Rivaroxaban Submitted for EU Marketing Authorisation in Stroke Prevention in Patients with Atrial Fibrillation as well as for the Treatment of Deep Vein Thrombosis January 04, 2011